These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 17662154

  • 1. Analysis of the cellular centrosome in fine-needle aspirations of the breast.
    Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, Gao Y, Pan QJ.
    Breast Cancer Res; 2007; 9(4):R48. PubMed ID: 17662154
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 6. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER, Tubbs RR, Myles JL, Procop GW.
    Am J Clin Pathol; 2002 Jun 01; 117(6):916-21. PubMed ID: 12047143
    [Abstract] [Full Text] [Related]

  • 7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R, Wahab NA, Yadav MM, Kutty MK.
    Oncol Rep; 2002 Jun 01; 9(2):409-16. PubMed ID: 11836618
    [Abstract] [Full Text] [Related]

  • 8. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
    Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW.
    Am J Clin Pathol; 2005 Aug 01; 124(2):273-81. PubMed ID: 16040300
    [Abstract] [Full Text] [Related]

  • 9. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C.
    Cancer Res; 1997 Oct 01; 57(19):4360-7. PubMed ID: 9331099
    [Abstract] [Full Text] [Related]

  • 10. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K, Oda M, Ogawa K, Tominaga K, Kaneko Y, Shimizu T, Matsumoto S, Oda M, Kurita Y, Taira Y.
    Jpn J Clin Oncol; 2013 Jan 01; 43(1):55-62. PubMed ID: 23225912
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HER2 genetic heterogeneity in breast carcinoma.
    Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W.
    J Clin Pathol; 2011 Dec 01; 64(12):1112-6. PubMed ID: 22011446
    [Abstract] [Full Text] [Related]

  • 13. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ, Hyjek E, Early E, Knowles DM.
    Int J Surg Pathol; 2006 Oct 01; 14(4):279-84. PubMed ID: 17041191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors.
    Tse GM, Cheung HS, Pang LM, Chu WC, Law BK, Kung FY, Yeung DK.
    AJR Am J Roentgenol; 2003 Nov 01; 181(5):1267-72. PubMed ID: 14573418
    [Abstract] [Full Text] [Related]

  • 16. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS, Apple SK.
    Breast J; 2009 Nov 01; 15(2):146-54. PubMed ID: 19292800
    [Abstract] [Full Text] [Related]

  • 17. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F, Shen T, Prichard JW.
    Diagn Cytopathol; 2005 Dec 01; 33(6):376-80. PubMed ID: 16299744
    [Abstract] [Full Text] [Related]

  • 18. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
    Heintz NH, Leslie KO, Rogers LA, Howard PL.
    Arch Pathol Lab Med; 1990 Feb 01; 114(2):160-3. PubMed ID: 1967929
    [Abstract] [Full Text] [Related]

  • 19. Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.
    Niu Y, Wang S, Liu T, Zhang T, Wei X, Wang Y, Jiang L.
    Pathol Res Pract; 2013 Apr 01; 209(4):221-7. PubMed ID: 23523041
    [Abstract] [Full Text] [Related]

  • 20. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
    Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ.
    J Pathol; 2003 Sep 01; 201(1):75-82. PubMed ID: 12950019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.